---
id: tmp-smx-pcp-prophylaxis_177
category: antimicrobials
tags: [tmp-smx, pcp, pneumocystis, prophylaxis, hiv, cd4]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## TMP-SMX - PCP Prophylaxis

**Q:** What are the indications for PCP prophylaxis, the preferred regimen (TMP-SMX dosing), and when can it be safely discontinued?

**A:**

## INDICATIONS FOR PCP PROPHYLAXIS

**Mnemonic: "CD4-STEROIDS-TRANSPLANT-MALIGNANCY"**

### **HIV Patients (Primary Prophylaxis):**

**Absolute Indications:**
1. **CD4 count <200 cells/μL** (OR CD4% <14%)
2. **Oropharyngeal candidiasis** (thrush - regardless of CD4)
3. **History of AIDS-defining illness** (regardless of CD4)

**Key Point:** **CD4 <200 = absolute indication** for PCP prophylaxis

---

### **Non-HIV Immunocompromised Patients:**

**Prolonged High-Dose Corticosteroids:**
- **Prednisone ≥20mg/day for ≥1 month** (OR equivalent)
- **Risk increases:** >4 weeks of therapy

**Hematologic Malignancies:**
- **Acute lymphoblastic leukemia (ALL)** - during induction/consolidation
- **Allogeneic hematopoietic cell transplant (HCT)** - during immunosuppression

**Solid Organ Transplant (SOT):**
- **First 3-6 months post-transplant** (highest risk period)
- **During treatment for rejection** (high-dose steroids + intensified immunosuppression)
- **Lung transplant:** Lifelong prophylaxis (highest risk - 20-40% without prophylaxis)

**Autoimmune Diseases on Intensive Immunosuppression:**
- **Granulomatosis with polyangiitis (GPA)** - during induction (cyclophosphamide + steroids)
- **Rheumatologic diseases** - if prednisone ≥20mg/day + other immunosuppressants

**Key Point:** **Steroids ≥20mg/day x ≥1 month = PCP prophylaxis** (non-HIV)

---

## TMP-SMX DOSING REGIMENS

**Mnemonic: "DS-DAILY-OR-3X-WEEK"**

### **Preferred Regimen (First-Line):**

**TMP-SMX Double Strength (DS):**
- **Dose:** 1 DS tablet (160mg TMP / 800mg SMX) PO daily
- **Efficacy:** **>95%** (gold standard)

**Key Point:** **1 DS tablet PO daily = preferred regimen** (>95% efficacy)

---

### **Alternative TMP-SMX Regimens (If Tolerability Issues):**

**Three Times Weekly:**
- **Dose:** 1 DS tablet (160/800mg) PO 3x/week (e.g., Mon-Wed-Fri)
- **Efficacy:** 90-95% (nearly equivalent to daily)
- **Use:** Better tolerability (fewer adverse effects)

**Single Strength (SS) Daily:**
- **Dose:** 1 SS tablet (80mg TMP / 400mg SMX) PO daily
- **Efficacy:** 85-90%
- **Use:** Better tolerability (fewer adverse effects)

**Key Point:** **3x/week = 90-95% efficacy** (alternative if daily not tolerated)

---

## ALTERNATIVE REGIMENS (If TMP-SMX Intolerant)

**Mnemonic: "DAPSONE-ATOVAQUONE-PENTAMIDINE"**

### **Dapsone:**
- **Dose:** 100mg PO daily
- **Efficacy:** 85-90%
- **Advantage:** Oral, well-tolerated
- **Disadvantages:**
  - **NO Toxoplasma coverage** (unlike TMP-SMX)
  - **G6PD deficiency contraindication** (hemolysis risk)
  - **Screen for G6PD deficiency before starting**

**Enhanced Regimen (Dapsone + Pyrimethamine + Leucovorin):**
- **Dose:** Dapsone 50mg + pyrimethamine 50mg + leucovorin 25mg PO weekly
- **Advantage:** **Provides Toxoplasma coverage** (unlike dapsone alone)

**Key Point:** **Dapsone alone = NO Toxoplasma coverage** | **Check G6PD first** (hemolysis risk)

---

### **Atovaquone:**
- **Dose:** 1500mg PO daily (with food - high-fat meal increases absorption 2-3x)
- **Efficacy:** 70-80% (inferior to TMP-SMX and dapsone)
- **Advantages:** Well-tolerated, no drug interactions
- **Disadvantages:**
  - **Expensive** ($500-1000/month)
  - **NO Toxoplasma coverage** (unlike TMP-SMX)
  - **Requires high-fat meal** for absorption

**Key Point:** **Atovaquone = least effective** (70-80%) | **Expensive, requires high-fat meal**

---

### **Aerosolized Pentamidine:**
- **Dose:** 300mg inhaled monthly (via Respigard II nebulizer)
- **Efficacy:** 60-70% (LEAST effective)
- **Advantages:** Minimal systemic toxicity
- **Disadvantages:**
  - **NO Toxoplasma coverage**
  - **NO coverage of upper lobes** (deposition limited to lower lobes)
  - **Risk of pneumothorax** (1-5%)
  - **Cough, bronchospasm** (common)
  - **Requires specialized equipment**

**Key Point:** **Pentamidine = least effective** (60-70%) | **No upper lobe coverage, no Toxoplasma**

---

## DISCONTINUATION OF PROPHYLAXIS (HIV Patients)

**Mnemonic: "CD4-ABOVE-200-FOR-3-MONTHS"**

### **Primary Prophylaxis:**

**Safe to Discontinue If:**
1. **CD4 count >200 cells/μL for ≥3 months** (confirmed on 2 measurements)
2. **Virologic suppression on ART** (undetectable HIV viral load)

**Key Point:** **CD4 >200 x 3 months + undetectable VL = stop prophylaxis**

---

### **Secondary Prophylaxis (Prior PCP):**

**Safe to Discontinue If:**
1. **CD4 count >200 cells/μL for ≥3 months** (confirmed on 2 measurements)
2. **Virologic suppression on ART**
3. **Completed full treatment course** for prior PCP

**Key Point:** **Same criteria as primary prophylaxis** (CD4 >200 x 3 months + undetectable VL)

---

### **Restart Prophylaxis If:**

**CD4 count drops <200 cells/μL** (even if transiently)

**Key Point:** **Restart if CD4 <200** (even transiently)

---

## DISCONTINUATION OF PROPHYLAXIS (Non-HIV Patients)

**Mnemonic: "STEROIDS-STOPPED-TRANSPLANT-STABLE"**

### **Corticosteroid-Induced Immunosuppression:**

**Safe to Discontinue If:**
- **Prednisone tapered to <20mg/day** (OR equivalent)
- **Duration of high-dose steroids <1 month** (short course)

### **Solid Organ Transplant:**

**Kidney/Liver/Heart Transplant:**
- **Discontinue after 3-6 months** (if no rejection episodes)

**Lung Transplant:**
- **Lifelong prophylaxis** (due to persistently high risk)

### **Hematologic Malignancy:**

**ALL:**
- **Continue through induction/consolidation** (entire treatment course)

**Allogeneic HCT:**
- **Continue until CD4 >200 cells/μL AND off immunosuppression** (usually 6-12 months)

**Key Point:** **Lung transplant = lifelong** | **Other SOT = 3-6 months**

---

## BREAKTHROUGH PCP (Despite Prophylaxis)

**Incidence:** 1-5% (rare with TMP-SMX)

**Risk Factors:**
- **Poor adherence** (most common cause)
- **Inadequate dosing** (e.g., 1 SS tablet vs 1 DS tablet)
- **Alternative regimens** (dapsone, atovaquone, pentamidine - less effective)
- **Severe immunosuppression** (CD4 <50 cells/μL in HIV)

**Management:**
- **Treat PCP** (full treatment dose TMP-SMX OR alternative if intolerant)
- **Resume prophylaxis after treatment** (consider switching regimen if adherent)

**Key Point:** **Breakthrough PCP = check adherence first** (most common cause)

---

## TOXOPLASMA PROPHYLAXIS (Bonus Coverage)

**TMP-SMX = ONLY PCP prophylaxis regimen that also covers Toxoplasma:**

**Toxoplasma Prophylaxis Indication (HIV):**
- **CD4 <100 cells/μL + positive Toxoplasma IgG** (latent infection)

**Regimen:**
- **1 DS tablet PO daily** (same as PCP prophylaxis)

**Discontinuation:**
- **CD4 >200 cells/μL for ≥3 months + undetectable VL**

**Key Point:** **TMP-SMX = ONLY regimen covering both PCP + Toxoplasma**

---

**Clinical Pearls:**
- **CD4 <200 = absolute indication** for PCP prophylaxis (HIV)
- **Steroids ≥20mg/day x ≥1 month = PCP prophylaxis** (non-HIV)
- **1 DS tablet PO daily = preferred regimen** (>95% efficacy)
- **3x/week dosing = 90-95% efficacy** (alternative if daily not tolerated)
- **CD4 >200 x 3 months + undetectable VL = stop prophylaxis**
- **Restart if CD4 <200** (even transiently)
- **Lung transplant = lifelong prophylaxis** | **Other SOT = 3-6 months**
- **Dapsone alone = NO Toxoplasma coverage** | **Check G6PD first**
- **Atovaquone = least effective** (70-80%) | **Expensive, requires high-fat meal**
- **Pentamidine = least effective** (60-70%) | **No upper lobe coverage, no Toxoplasma**
- **TMP-SMX = ONLY regimen covering both PCP + Toxoplasma**
- **Breakthrough PCP = check adherence first** (most common cause)

**Media:**

**Additional Resources:**
- **DHHS Guidelines:** PCP prophylaxis in HIV
- **IDSA Guidelines:** PCP prophylaxis in non-HIV immunocompromised
- **CDC Guidelines:** Opportunistic infection prophylaxis

**Sources:** [DHHS OI Guidelines], [IDSA PCP Guidelines], [CDC OI Prevention]
